MultiSeq-AMR: A modular amplicon-sequencing workflow for rapid detection of bloodstream infection and antimicrobial resistance markers

Mohammad Saiful Islam Sajib,Katarina Oravcova,Kirstyn Brunker,Paul Everest,Ma Jowina H. Galarion,Manuel Fuentes,Catherine Wilson,Michael E. Murphy,Taya Forde
DOI: https://doi.org/10.1101/2024.10.25.24316117
2024-10-27
Abstract:Bloodstream infections (BSI) represent a significant global health challenge, and traditional diagnostic methods are suboptimal for timely guiding targeted antibiotic therapy. We introduce MultiSeq-AMR, an ultra-fast amplicon sequencing workflow to identify bacterial and fungal species, and a comprehensive set of antimicrobial resistance (AMR) genes (n = 91) for BSI diagnosis. We initially benchmarked MultiSeq-AMR using DNA from 21 bacterial and fungal isolates and accurately identified 100% species and 99.4% AMR genes. Further validation with 33 BACT/ALERT positive samples from suspected BSI cases revealed 100% accuracy for pathogen identification with mono-bacterial samples, with 97.4% categorical agreement (CA) for AMR gene prediction. To accelerate diagnosis, 6-hour culture-enrichment combined with MultiSeq-AMR identified 11/13 species with 96% CA for AMR gene identification. MultiSeq-AMR holds promise for improving patient outcomes as species/AMR genes could be identified in under 5 hours of BACT/ALERT positivity, and potentially <11 hours of sample collection.
Infectious Diseases (except HIV/AIDS)
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the speed and accuracy of blood - stream infection (BSI) diagnosis. Traditional diagnostic methods have a delay in guiding targeted antibiotic treatment, which may lead to poor patient prognosis, especially in the case of early - onset sepsis symptoms. Therefore, the paper introduces a rapid amplicon sequencing workflow named Mul*Seq - AMR, aiming to identify bacterial and fungal species as well as a comprehensive set of antimicrobial resistance (AMR) genes, in order to accelerate the diagnosis of BSI. Specifically, Mul*Seq - AMR addresses these problems in the following ways: 1. **Rapid diagnosis**: Mul*Seq - AMR can identify species and AMR genes from BACT/ALERT - positive samples within less than 5 hours, thereby significantly shortening the diagnosis time. 2. **High accuracy**: Verified by using reference strains and clinical samples, Mul*Seq - AMR shows high accuracy in species identification and AMR gene prediction. 3. **Cost - effectiveness**: Even at a lower sequencing output (such as 2 Mbp), Mul*Seq - AMR can still maintain high detection sensitivity and specificity, reducing the sequencing cost. 4. **Modular design**: The workflow of Mul*Seq - AMR is modular and can be flexibly adjusted to meet different clinical needs. In conclusion, Mul*Seq - AMR aims to improve patient treatment outcomes and reduce the risk of antibiotic abuse by increasing the speed and accuracy of diagnosis.